Back

Icosapent ethyl: what are the most likely mechanisms of benefit?

7 April 2022 (16:35 - 16:45)
Organised by:
Congress Presentation Part of: Cardiovascular risk reduction beyond statin therapy: exploring the role of icosapent ethyl Treatment Open Access ESC Preventive Cardiology 2022

About the speaker

Photo
Professor Chris Packard

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Introduction.
Professor U. Laufs (Leipzig, DE)
Slides
Presentation thumbnail
Assessing residual cardiovascular risk in patients already treated with statin therapy.
Professor A. Zambon (Padua, IT)
Video
Presentation thumbnail
Exploring the role of icosapent ethyl based on current clinical evidence.
Professor J. Jukema (Leiden, NL)
Video
Presentation thumbnail
Discussion.

Access the full session

Session thumbnail
Cardiovascular risk reduction beyond statin therapy: exploring the role of icosapent ethyl
Video

The Event

Event poster

ESC Preventive Cardiology 2022

7 April 2022 16:35 CET
You may be interested in
thumbnail
Congress Session
New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice
26 August 2022
thumbnail
Congress Presentation
Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
27 August 2022
thumbnail
Congress Presentation
REDUCE-IT: outcomes by baseline statin type
28 August 2020
thumbnail
Congress Presentation
Cardiovascular risk reduction & hypertriglyceridemia: integrating the evidence
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources